Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Tremfya showed greater persistence in bio-naïve and ...

Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class investigational targeted oral peptide that ...

Guselkumab significantly and rapidly improved severe scalp psoriasis, itch, and patient-reported health-related quality of life outcomes in people of color. Guselkumab shows rapid and significant ...

Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Deucravacitinib maintained efficacy and safety when ...

Working on fast cars has been Rogelio "Al" Castro's lifelong passion. Now, in retirement, he loves to take his grandkids to the speedway and tell them what it was like when he worked in the pit - the ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...